Example: Heart Attack

Search clinical trials for: Kallikreins

Total 44 results

NCT02562183

Unknown status

The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein

Conditions: Cerebral Infarction
NCT04102956

Completed

The Effect of Human Urinary Kallikrein on Corticospinal Tract Injury in Acute Ischemia Stroke Patients

Conditions: Stroke, Acute
NCT04325932

Withdrawn

Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis

Conditions: Intracranial Arteriosclerosis; Collateral Circulation; Anterior Cerebral Circulation Infarction
NCT01558245

Unknown status

Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis

Conditions: Cerebrovascular Disease
NCT04020666

Completed

Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism

Conditions: Acute Ischemic Stroke; Abnormal Glucose Metabolism
NCT04130776

Completed

4Kscore Using Serum Stored Uncentrifuged

Conditions: Prostate Cancer
NCT02259738

Completed

Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase

Conditions: Cerebral Infarction
NCT03290560

Completed

Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

Conditions: Acute Ischemic Stroke
NCT03431909

Completed

Evaluation Of HUK in Acute Stroke Patients: MRS and CTP

Conditions: Acute Ischemic Stroke
NCT02806128

Unknown status

The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship

Conditions: Cerebral Infarction
NCT02868996

Completed

An Open Label, Phase 1b, Ascending Dose Study of DM199

Conditions: Stroke
NCT04549922

Active, not recruiting

Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19

Conditions: Covid19
NCT02070575

Active, not recruiting

Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence

Conditions: Prostate Cancer
NCT02193113

Completed

A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

Conditions: Diabetic Macular Edema
NCT01845064

Completed

A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients

Conditions: Diabetes Type 2
NCT00395005

Completed

Correlation of Urinary Kallikrein With Cytokines, Proteinuria and Renal Function in Chronic Renal Disease Patients

Conditions: Chronic Kidney Disease
NCT01036659

Unknown status

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Conditions: Angioedema
NCT04644770

Recruiting

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Conditions: Prostatic Neoplasms; Adenocarcinoma
NCT03466099

Completed

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Conditions: Diabetic Macular Edema
NCT04597944

Recruiting

Lanadelumab in Bradykinin Angioedema

Conditions: Angioedema
NCT00155064

Completed

Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism

Conditions: Hyperaldosteronism
NCT01398280

Completed

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

Conditions: Rosacea
NCT00005261

Completed

Urinary Kallikrein and Hypertension: A Prospective Study

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension
NCT04278885

Recruiting

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

Conditions: Hereditary Autoinflammatory Disease
NCT04116164

Recruiting

Safety and Targeting of Anti-hk2 Antibody in mCRPC

Conditions: Castration-Resistant Prostatic Cancer; Metastatic Disease